Mei Hou
Impact in
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Oncology top 2%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
Papers in
-
- Lung Cancer Treatments and Mutations 9
- Brain Metastases and Treatment 2
- Oncology 9
- Lung Cancer Research Studies 7
- Colorectal Cancer Treatments and Studies 2
- Co-authors
- Chengping Hu (8 shared papers)Shun Lü (6 shared papers)Yi‐Long Wu (6 shared papers)Jifeng Feng (6 shared papers)Yunchao Huang (5 shared papers)Jian Hua Shi (5 shared papers)Dan Massey (4 shared papers)Wěi Li (4 shared papers)
- Journals
- Journal of Clinical Oncology (4 papers)BMC Cancer (3 papers)Medical Oncology (2 papers)Scientific Reports (1 paper)Cancer Chemotherapy and Pharmacology (1 paper)
- Partner nations
- ChinaUnited KingdomThailand
In The Last Decade
Mei Hou
38 papers receiving 2.5k citations
Mei Hou's Hit Papers
Peers
Comparison fields: 5 of 101
- Pulmonary and Respiratory Medicine 1.6k
- Oncology 1.1k
- Cancer Research 386
- Molecular Biology 573
- Gastroenterology 27
Countries citing papers authored by Mei Hou
This map shows the geographic impact of Mei Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mei Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mei Hou more than expected).
Fields of papers citing papers by Mei Hou
This network shows the impact of papers produced by Mei Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mei Hou. The network helps show where Mei Hou may publish in the future.
Co-authors
The 25 scholars most cited alongside Mei Hou, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Hit paper breakdown → | 2014 | 1589 |
| 2 | 2009 | 180 | |
| 3 | 2011 | 75 | |
| 4 | 2016 | 71 | |
| 5 | 2013 | 65 | |
| 6 | 2013 | 59 | |
| 7 | 2023 | 52 | |
| 8 | 2009 | 50 | |
| 9 | 2015 | 49 | |
| 10 | 2010 | 48 | |
| 11 | 2016 | 37 | |
| 12 | 2016 | 26 | |
| 13 | 2008 | 26 | |
| 14 | 2010 | 22 | |
| 15 | 2023 | 22 | |
| 16 | 2018 | 22 | |
| 17 | 2013 | 17 | |
| 18 | 2017 | 16 | |
| 19 | 2013 | 14 | |
| 20 | 2006 | 12 |
About Mei Hou
Mei Hou is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Neurology and Epidemiology, having authored 39 papers that have together received 2.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (7 papers), Neurofibromatosis and Schwannoma Cases (2 papers), Kruppel-like factors research (2 papers), Colorectal Cancer Treatments and Studies (2 papers), Fibroblast Growth Factor Research (2 papers), Brain Metastases and Treatment (2 papers) and Gastrointestinal Tumor Research and Treatment (2 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.6k citations), Oncology (1.1k citations), Cancer Research (386 citations), Molecular Biology (573 citations) and Gastroenterology (27 citations). Mei Hou has collaborated with scholars based in China, United Kingdom and Thailand. Frequent co-authors include Chengping Hu, Shun Lü, Yi‐Long Wu, Jifeng Feng, Yunchao Huang, Jian Hua Shi, Dan Massey, Wěi Li, Yang Shi and Kye Young Lee. Their work appears in journals such as Journal of Clinical Oncology, BMC Cancer, Medical Oncology, Scientific Reports and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.